account_id none on file
legal_name Immunome Inc.
ticker IMNM
cik 1472012
domain immunome.com
linkedin_company_url https://www.linkedin.com/company/immunome-inc-
entry_point_account_id none on file
exchange Nasdaq
sector Health Care
hq Bothell, WA, United States
sector index/company/sector/health-care/
calls 0 filings 4 executives 3 family 0
why_nownone on file
callsnone on file
filings
The increase was primarily related to increases in expenses related to commercialization readiness, as well as an increase in personnel-related costs including share-based compensation from an increase in headcount to support overall growth.
filing / Aug 11, 2026 / receipt
The increase was primarily a result of a $1.8 million increase in personnel-related costs from an increase in headcount, including a $1.0 million increase in share-based compensation.
filing / May 12, 2026 / receipt
Commercial hires have demonstrated success in oncology launches
ir_statement / Sep 15, 2026 / receipt
Launch focused on 85 sarcoma centers of excellence expected to drive efficiency and quick uptake
ir_statement / Sep 15, 2026 / receipt
executives
| Corleen M. Roche | Chief Financial Officer | - | receipt |
| Diane Marcou | Interim Chief Financial Officer | - | receipt |
| Max Rosett | Chief Financial Officer | receipt |
familynone on file
upcoming
| 2026-11-05 | earnings call | scheduled | ir |
changes
| 2023-12-29 | Interim Chief Financial Officer, appointed | sec_8k |
| 2021-04-20 | Chief Financial Officer, appointed | sec_8k |
| 2020-12-04 | Chief Financial Officer, departed | sec_8k |
| 2020-12-04 | Interim Chief Financial Officer, appointed | sec_8k |
mcp_package_hint
slug immunome-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$